Skip to main content
Lesedauer ca. 3 Min. 22. September 2026

WHEN EVIDENCE MEETS EXPERIENCE

A physician–patient conversation on shared treatment decisions in retinal care

Company & Network Research & Evidence
HCP-Patient-Dialogue

How do physicians and patients make good treatment decisions when a disease is progressive, treatment options are limited and the evidence continues to evolve?

Anja Renner and Prof. Hendrik Scholl talk openly about clinical evidence, individual expectations, uncertainty and what shared decision-making means in practice.

Friday, 2 October 2026 | 14:45–15:15
Booth E53 | EURETINA, VIECON Vienna

Add to calendar

Two perspectives. One shared decision.

Scientific evidence is essential. But every treatment decision is ultimately made for an individual patient.

The physician brings clinical evidence, medical experience and responsibility.
The patient brings personal priorities, expectations and the lived experience of progressive vision loss.

The conversation explores what happens when these two perspectives come together – and what good shared decision-making can look like in practice.

The physician’s perspective

Prof. Hendrik Scholl brings the clinical perspective:

What evidence does a retinal specialist need before considering a treatment option? How should remaining uncertainties be assessed and communicated? And when does a possible option become a treatment that can reasonably be discussed with an individual patient?

The patient’s perspective

Anja Renner lives with a progressive retinal disease and uses OkuStim.

What do patients need in order to make an informed treatment decision? How are potential benefit, uncertainty and treatment burden weighed against each other? And what role does the conversation with the treating physician play?

Listen in

The conversation will be transmitted via our LiveVoice Silent Conferencing system, allowing you to listen directly at our booth using your own smartphone and headphones.

Before the event:
Download the free LiveVoice app and bring your own headphones.

At the booth, simply scan the LiveVoice QR code or enter the event code provided on site.

No registration or LiveVoice account is required.

[LIVEVOICE ACCESS – available shortly]

Don’t miss the conversation

Friday, 2 October 2026
14:45–15:15
Booth E53 | EURETINA, VIECON Vienna

Add to calendar

Insights onTherapy, Research & Company

Okuvision – Preserving Vision. Protecting Quality of Life.

Okuvision develops innovative therapeutic solutions for people living with retinitis pigmentosa (RP), an inherited retinal disease that can lead to progressive vision loss. With OkuStim®, we offer an evidence-based therapy designed to slow disease progression and help patients preserve their vision for longer. Together with patients, ophthalmologists, and research partners, we are committed to advancing innovative treatment options and improving quality of life.

ContactPartners & Sources of Supply

The OkuStim® therapy was developed for patients with degenerative retinal diseases such as retinitis pigmentosa. It may help slow the progression of the disease. At the core of the therapy is the OkuStim® System, which enables you to stimulate your retina independently at home using low-level electrical currents.

Learn more about Clinical Evidence

Okuvision products are not for sale in the USA.